NCT05945602 Neurophysiologic Biomarkers for Cognitive Rehabilitation
| NCT ID | NCT05945602 |
| Status | Recruiting |
| Phase | — |
| Sponsor | VA Office of Research and Development |
| Condition | Schizophrenia Spectrum Disorders |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2023-10-01 |
| Primary Completion | 2028-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2023-10-01 with a primary completion date of 2028-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cognitive symptoms of schizophrenia interfere with daily life-from managing self-care, to more complex tasks like taking medications and living independently. Unfortunately, these cognitive symptoms are not corrected by 'standard of care' treatments (antipsychotic medications), although some schizophrenia patients may experience modest clinical and cognitive benefits from cognitive remediation. To enhance the clinical impact of cognitive remediation and other rehabilitative interventions for Veterans living with chronic psychosis, this study will develop novel brain-based tools to help identify those Veterans who are most likely to benefit from pro-cognitive therapies. These studies may advance predictive algorithms that improve functional outcomes and life quality in Veterans with schizophrenia.
Eligibility Criteria
Inclusion Criteria: 1. Have a DSM-5 diagnosis of a chronic psychotic disorder (e.g., schizophrenia, schizoaffective disorder, or delusional disorder); or b) are in good general mental and physical health (i.e., no active mental health condition). 2. Fluent in spoken and written English. 3. No impairment in hearing or vision. Exclusion Criteria: 1. Active substance other than cannabis within the last 30 days as determined by self-report or positive urine toxicology (obtained as part of the screening process). 2. History of significant medical or neurological illness or intellectual disability. 3. Inability to comprehend or provide informed consent. 4. Specific to healthy comparison subjects: past or present diagnosis of schizophrenia, schizoaffective disorder, or other chronic psychotic disorder.
Contact & Investigator
Juan Molina, MD
PRINCIPAL INVESTIGATOR
VA San Diego Healthcare System, San Diego, CA
Frequently Asked Questions
Who can join the NCT05945602 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Schizophrenia Spectrum Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05945602 currently recruiting?
Yes, NCT05945602 is actively recruiting participants. Contact the research team at Juan.Molina@va.gov for enrollment information.
Where is the NCT05945602 trial being conducted?
This trial is being conducted at San Diego, United States.
Who is sponsoring the NCT05945602 clinical trial?
NCT05945602 is sponsored by VA Office of Research and Development. The principal investigator is Juan Molina, MD at VA San Diego Healthcare System, San Diego, CA. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.